Topline data from the randomized Phase 2b KICKSTART trial of tomivosertib combined with pembrolizumab in non-small cell lung cancer expected in early April 2024 Median progression free survival of.
Topline data from the randomized Phase 2b KICKSTART trial of tomivosertib combined with pembrolizumab in non-small cell lung cancer (NSCLC) expected in early April 2024
Fort Lee, NJ, Feb. 09, 2024 Nuvectis Pharma, Inc. , a clinical-stage biopharmaceutical company focused on the development of innovative precision medicines for the treatment of serious.
Fort Lee, NJ, Feb. 09, 2024 Nuvectis Pharma, Inc. , a clinical-stage biopharmaceutical company focused on the development of innovative precision medicines for the treatment of serious.